Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Non-Surgical GentleCure™ Treatment Cures 50,000th Skin Cancer Patient

By: NewsUSA

(NewsUSA) -            Fifty thousand people in the U.S. have had their skin cancer cured without going to hospitals or undergoing traditional Mohs surgery, avoiding that treatment’s pain, bleeding, surgical scarring and, often, need for follow-up reconstructive surgery.

          The nation’s 50,000th case of curing common (nonmelanoma) skin cancer with GentleCure™, the non-surgical treatment using Image-Guided Superficial Radiation Therapy or Image-Guided SRT, occurred at Reading Dermatology, the private Pennsylvania practice of Jason Hendrix, DO.

          The patient was Jeffrey Keating, D.P.M., a 74-year-old retired podiatrist from Birdsboro, Pennsylvania, whose lifelong habits of golfing, sailing and driving in his top-down convertible likely contributed to his history of skin cancer.

          “I had Mohs surgery years earlier for a lesion on my calf,” Keating said, “but this time, with three lesions on my face, my doctor and I chose non-surgical GentleCure and the results were outstanding.”

          With GentleCure, doctors treat nonmelanoma skin cancer (basal and squamous cell carcinomas) using ultrasound imaging to direct low-level X-ray energy to targeted areas of the skin, killing cancer cells without surgery. Research shows that the technology produces a 99.3 percent cure rate for early stage nonmelanoma skin cancer, making it just as effective as Mohs surgery, and treatments are covered by Medicare and most insurance plans.

          Dr. Hendrix noted, "More than three million Americans are diagnosed with nonmelanoma skin cancer each year, making it the most common form of cancer. Sun exposure is the primary cause and year-round sun effects are cumulative over one's lifetime, so those who spend a lot of time outdoors plus seniors, those with light skin, users of tanning beds and people with family histories of skin cancer are especially susceptible. With all its advantages, GentleCure is the new non-invasive standard of care."

           Patient Keating added, “As a physician myself, I know that it’s critically important for patients to understand all their treatment options. Having experienced Mohs surgery, the idea of no pain or scarring with GentleCure was very attractive. Actually seeing the cancer shrink and disappear on the ultrasound imaging screen was so reassuring. I have a friend who had Mohs surgery on a facial lesion, and he had a flap of skin cut from his scalp and stretched over the site of his excised lesion; that was not something I wanted to experience. Today, I am fully cured and could not be happier with the GentleCure process and results.”

           For more information and to learn where Image-Guided SRT is available, visit GentleCure.com.

 

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.